PDL BioPharma

PDLI NASDAQ
3.000
+0.010
+0.33%
Closed 16:00 06/18 EDT
Open
2.990
Prev Close
2.990
High
3.030
Low
2.950
Volume
822.30K
Avg Vol (3M)
1.18M
52 Week High
3.890
52 Week Low
2.250
% Turnover
0.68%
Market Cap
361.96M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers PDL BioPharma PDLI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
MORE >

Recently

Name
Price
%Change